Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,

Vesna Najfeld, PhD, John Mascarenhas, MD, Steven Fruchtman, MD, Samuel Cytryn, Marina Kremyanskaya, MD, Joseph Tripodi, MS, Ronald Hoffman, MD

Blood (2011) 118 (21): 3526.

https://doi.org/10.1182/blood.V118.21.3526.3526

Published: 2011

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Maria J. Nieto, MD, Eileen Scigliano, MD, Celia L. Grosskreutz, MD, Steven Fruchtman, MD, John Mascarenhas, MD, Keren Osman, MD, Adriana Malone, MD, Samuel Cytryn, Vesna Najfeld, PhD, Ronald Hoffman, MD, Luis Isola, MD

Blood (2011) 118 (21): 4534.

https://doi.org/10.1182/blood.V118.21.4534.4534

Published: 2011

Journal Articles

Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).

Vesna Najfeld, Ph.D., Joseph Tripodi, Steven Fruchtman, MD, Lewis R. Silverman, MD, Richard T. Silver, MD, Angela Scalise, Ronald Hoffman, MD

Blood (2009) 114 (22): 1567.

https://doi.org/10.1182/blood.V114.22.1567.1567

Published: 2009

Journal Articles

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

Steven M. Horwitz, MD, Julie M. Vose, M.D., Ranjana Advani, MD, Kamalesh Sankhala, MD, Swaminathan Padmanabhan, MD, Paul A. Hamlin, Jr., MD, Andy Chen, MD, PhD, Jasmine M Zain, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1674.

https://doi.org/10.1182/blood.V114.22.1674.1674

Published: 2009

Journal Articles

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).

Lauren Pinter-Brown, Steven M. Horwitz, MD, Barbara Pro, MD, Pier Luigi Zinzani, MD, Christian Gisselbrecht, MD, Barbara MacGregor Cortelli, RN, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1675.

https://doi.org/10.1182/blood.V114.22.1675.1675

Published: 2009

Journal Articles

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 919.

https://doi.org/10.1182/blood.V114.22.919.919

Published: 2009

Journal Articles

Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).

Kerry J. Savage, MD, Andrei R. Shustov, MD, Andre Goy, MD, Steven M. Horwitz, MD, Barbara Pro, MD, Molly Patterson, BA, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1678.

https://doi.org/10.1182/blood.V114.22.1678.1678

Published: 2009

Journal Articles

Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis.

Barbara Pro, MD, Bertrand Coiffier, MD, Steven M. Horwitz, MD, Adam Boyd, PhD, Ellen Neylon, RN, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1681.

https://doi.org/10.1182/blood.V114.22.1681.1681

Published: 2009

Journal Articles

Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy.

Leslie Popplewell, MD, Barbara Pro, MD, Eric Jacobsen, MD, Steven M. Horwitz, MD, Adam Boyd, PhD, Molly Patterson, BA, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 3420.

https://doi.org/10.1182/blood.V114.22.3420.3420

Published: 2009

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, MD, Celia Grosskreutz, MD, Steven Fruchtman, MD, Janice Gabrilove, MD, John Mandeli, PhD, Luis Isola, MD

Blood (2005) 106 (11): 5315.

https://doi.org/10.1182/blood.V106.11.5315.5315

Published: 2005

Journal Articles

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

Damiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, Josef T. Prchal, Uday Popat, Emilio P. Alessandrino, Jerry L. Spivak, B. Douglas Smith, Hans G. Klingemann, Steven Fruchtman, Ronald Hoffman

Blood (2005) 105 (10): 4115–4119.

https://doi.org/10.1182/blood-2004-11-4299

Published: 2005

Journal Articles

Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial.

Vesna Najfeld, Ph.D., Richard T. Silver, MD, Ronald Hoffman, MD, August Salvado, MD, Rona Weinberg, Ph.D., Steven Fruchtman, MD

Blood (2004) 104 (11): 2431.

https://doi.org/10.1182/blood.V104.11.2431.2431

Published: 2004

NARROW

Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression,

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).

Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis.

Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy.

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only